Grass City 20% OFF

HENDERSON, NV / ACCESSWIRE / November 13, 2018 / Last Tuesday’s election was great news for cannabis companies. With Michigan approving recreational marijuana and several other measures passing investors are beginning to grow more and more confident in companies in the space.

Looking at options in the space Inc. (CIIX) is one of the more intriguing CBD companies. CIIX focused on the sales of industrial hemp-based CBD products in China, the company just reported impressive numbers including 70% increase in revenue and an 800% sales increase. If this is the first time you are hearing about CIIX start doing your own due diligence immediately. CIIX could start receiving increased attention from the street at anytime.

CBD stocks to watch include:, Inc. (CIIX), GW Pharmaceuticals plc (NASDAQ:GWPH), Cronos Group, Inc. (NASDAQ:CRON), Aurora Cannabis, Inc. (NYSE:ACB), and Terra Tech Corp. (TRTC)., Inc. (CIIX)

Market Cap: $23.43M Share Price: $0.635, Inc. (CIIX) presented at the National Investment Banking Association (NIBA) 145th investment conference, this past week at the Crowne Plaza Times Square in New York City.

NIBA has been connecting companies with funding and liquidity sources for over 35 years, with a successful track record that includes raising (USD) billions for micro-cap and small-cap companies.

Cronos Group, Inc. (NASDAQ:CRON)

Market Cap: $1.43B Share Price: $8.06

CRON will announce its financial results and hold its Third Quarter 2018 Earnings Conference Call on Tuesday, November 13, 2018, at 8:30 a.m. EDT. Senior management will be available for questions from the investment community after prepared remarks.

GW Pharmaceuticals plc (NASDAQ:GWPH)

Market Cap: $4.71B Share Price: $145.71

GW Pharmaceuticals (NASDAQ:GWPH) announced that its EPIDIOLEX® (cannabidiol) oral solution CV is now available in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018, is the first prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs.

Aurora Cannabis, Inc. (NYSE:ACB)

Market Cap: $7.19B Share Price: $7.49

Aurora Cannabis Inc. (NYSE:ACB), just announced the official opening of its latest high-tech cannabis production facility in Lachute, Quebec; the company is calling it “Eau.”

At 48,000 square feet, with 11 purpose-built grow rooms, Aurora Eau will produce up to 4,500 kg of high quality cannabis per year, all in a facility with some of the lowest electricity costs in North America. It is designed to grow niche varieties of cannabis for the premium medical and adult consumer use markets in Quebec, Canada and around the world. Eau becomes Aurora’s second production facility in Quebec , the first being Aurora Vie, a 40,000 square foot indoor grow facility in Pointe Claire, Quebec .

Terra Tech Corp. (TRTC)

Market Cap: $122.28M Share Price: $1.57

Terra Tech Corp. (TRTC) a vertically integrated cannabis-focused agriculture company, announced that it signed a non-binding letter of intent to merge with Golden Leaf Holdings, Ltd., a cannabis company with cultivation, production and retail operations built around recognized brands. Under the terms of the letter of intent, a wholly owned subsidiary of Terra Tech will amalgamate with Golden Leaf, with the resulting amalgamated corporation being a wholly owned subsidiary of Terra Tech. Consummation of the transaction is subject to a number of conditions, including entering into a mutually agreed definitive arrangement agreement, completion of due diligence, the waiting period for the Hart-Scott-Rodino Act, state and local regulatory approvals, approval by the Ontario courts, Terra Tech board approval, Golden Leaf receiving a positive fairness opinion, Canadian Securities Exchange approval and Golden Leaf shareholder and board approval.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (”Regal Consulting”). Regal Consulting has agreed to a five month term consulting agreement with the CIIX dated 8/2/18. The agreement calls for $30,000 in cash and 20,000 restricted 144 shares of CIIX per month. The Issuer CIIX has agreed to increase the monthly cash payment to $45,000 for September. Issuer has agreed to increase the monthly cash payment to $49,000 for October. Issuer has agreed to increase the monthly cash payment to $49,000 for November. All payments were made directly by, Inc. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to to distribute this article. Regal Consulting has a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. CIIX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice. Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager


Phone: 1-702-720-6310

Country: United States


SOURCE: ACR Communications LLC